Last reviewed · How we verify
PCV13
At a glance
| Generic name | PCV13 |
|---|---|
| Also known as | Prevnar 13 (Pfizer Inc.), 13-valent pneumococcal conjugate vaccine, Prevnar13, Prevenar 13, Prevenar13 |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1,PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (PHASE2)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |